# Adipo Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/adipo-therapeutics

- Industry: Biotechnology
- Headquarters: Indianapolis, US
- Website: www.adipotherapeutics.com
- Total disclosed funding: $1.9M
- Latest round: Seed (Jan 31, 2024)
- Investors on record: 4

## About

Based in Indiana, US, and founded by Meng Deng (President) in 2017, Adipo Therapeutics, LLC operates as a pre-clinical biotechnology company that offers therapy that utilizes polymer-based notch-inhibiting nanoparticles. In February 2024, the firm raised USD 1.9 million in seed funding led by investors Purdue Research Foundation, Elevate Ventures, IU Ventures, and VisionTech. The firm as of February 2024, is led by its CEO, Karen Wurster. 

The company is developing a treatment landscape for obesity and Type 2 diabetes mellitus (T2DM) by leveraging the power of brown fat. Adipo focuses on localized Notch inhibition, converting energy-storing white fat into energy-burning brown fat, thus enhancing daily energy expenditure and metabolic balance for millions affected by these conditions. Their approach involves the development of polymer-based nanoparticles that after injection into adipose (fat) tissue inhibit Notch signaling and induce browning of adipose tissue, leading to sustainable weight loss and improved glucose homeostasis.

The company plans to utilize the January 2023 funding for the development of its treatments.

## Funding rounds

- Seed, Jan 31, 2024, $1.9M — Elevate Ventures, Purdue Research Foundation, VisionTech Partners, IU Ventures

## Investors

- Elevate Ventures (https://capitalatlas.ai/funds/elevate-ventures) — Seed
- Purdue Research Foundation — Seed
- VisionTech Partners (https://capitalatlas.ai/funds/visiontech-partners) — Seed
- IU Ventures — Seed